ArticleJournal of cellular and molecular medicine2025
Monoclonal Antibodies to Thyrotropin Receptor With Thyroid-Stimulating Activity Activate the NF-κB Pathway to Induce Chemokine Expression.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artemisinin-Related Therapeutic Strategies for Autoimmune Thyroiditis: Chemokine-Receptor Networks, Spatial Thyroid Biology, and Molecular Mechanisms.Drug design, development and therapy · 2026Review
- Cytokines and drugs targeting cytokines in Graves' disease and thyroid eye disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The A subunit of thyrotropin receptor (TSHR) is thought to be the crucial gene mediating stimulatory autoantibodies in Graves' diease (GD), but it remains unclear what the molecular basis of this pathological antibody response is. Stimulatory TSHR autoantibodies may induce activation of multiple signalling pathways in GD, modulate chemokine exposure and further stimulate immune imbalance. In this study, we prepared TSHR 289 protein by using insect baculovirus expression, adenovirus-expressed TSHR289 immunised mice, and obtained three mouse anti-TSHR monoclonal antibodies (mAbs), 1A4, 7C3 and 22B1, by the hybridoma technique. Flow assay and ELISA tests tested the activity and competitive binding of the mAbs. After mAbs stimulation of human thyrocytes, RT-qPCR and ELISA were used to detect the expression of chemokine; Western blotting detected the expression of CCL19 and the level of phosphorylation of NF-κB. Nanogram concentrations of the IgG mAbs 1A4, 7C3 and 22B1 and their Fab induce TSHR stimulation. TRAb in the serum of GD patients competitively inhibits the binding of HRP-conjugated mAbs to TSHR on the coated plate. Injection of micrograms of 7C3 resulted in elevated serum thyroxine and columnar and papillary hyperplasia of thyroid follicular epithelial cells. All three mAbs induced distinct expression of CCL2, CCL19 and CCL5 by activating canonical and non-canonical NF-κB signalling pathways in human thyrocytes. Collectively, we obtained three mouse anti-TSHR mAbs which provide an improved approach to characterise the molecular basis of this pathological response, and confirmed that stimulating antibodies activate NF-κB, inducing chemokines involved in the autoimmune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.